Quality Assurance Study Of Real-Time Targeted Massive Parallel Sequencing (Mps) Comprehensive Cancer Panel (Ccp) And Network Pathway Analysis In Early Breast Cancer (Ebc)

11092 Background: We undertook a prospective quality assurance study in 63 women with early breast cancer (EBC) identifying technical issues that required modification for real-time integration of MPS with clinical and pathology parameters for clinical decision making. Methods: Pre-operatively, patients underwent a 2 step formal informed consent process. Samples were collected fresh into Qiagen PaxGene Tissue Container preserving both morphology and biomolecules with lysis of tissues overnight. Day 2 and 3; DNA extraction was performed using the Qiagen DSP kit over 1 hour. DNA and RNA MPS Ampliseq CCP was performed on Life technologies Proton P1 chip using in-house modifications in order to increase the fidelity of library preparation. Days 4-6 manually curated bioinformatics against publicly available mutation databases (e.g. COSMIC etc.) Day 7 communication of results. Results: The median age was 55, (32-84), 43 (66%) were postmenopausal. Histopathology IDC 47 (72%), ILC 8 (12%), NOS 5 (8%) metaplastic ...